14 Melanoma Marches down, 7 to go!
19 March 2018
The weather varied, with high temps in Canberra, Bunbury, Manly and Newcastle, while Adelaide and Bunbury bore the brunt of wind and some rain. Needless to say, all six Marches were overwhelming successes.
Bendigo, with a population of less than 100,000 people, has raised a whopping $16,000 for Melanoma Institute Australia. This is incredible and the feedback has been amazing, with the committee working tirelessly to put on what was a great event.
It was a beautiful morning in Newcastle, there was a breeze and it was very scenic down near Nobby’s beach. While emotions ran high, the sense of community was undeniable, with everyone supporting one another and all Marching for the same cause. With over 300 people attending the March, Newcastle has broken the $30,000 fundraising tally mark, which is a huge achievement.
Manly had a change of location and added an additional challenge. Participants tackled stand-up-paddle boarding on a 3km loop, while the majority Marched collectively, following the Fairlight walking path. With nearly 500 people registering at Manly, the event was a huge success.
Canberra reached big numbers with over 300 participants attending the March this year. Our country’s capital always produces a great atmosphere for Marchers to show support to those who have been affected by melanoma.
Bunbury, a small town in Western Australia held Melanoma March, and, for the first time ever included a 10km optional running track. In partnership with melanomaWA, Melanoma March Bunbury contributed to raising life-saved funds for melanoma research. Thank you to the committee and to melanomaWA for their continued support.
Thank you to all participants, committee members, supporters and to all. Melanoma March is a time to remember, honour and support those who have had or have melanoma. But there is still work to be done. We still have 7 Marches in various states to go, so let’s not lose momentum. It is time to end melanoma.
We sat down for a short Q&A with our Clinical Research Fellow Sangeetha Ramanujam.
Today marks International Clinical Trials Day held on May 20 each year celebrating how far clinicians have come in the field of research.
We sat down with MIA Practice Manager, Sherrie D'Souza and got an insight into the day of life of her role.
Dr Long was nomitated for the InStyle Women In Style Awards in the Science and Environment category.
The Federal Government’s 2015-16 Budget was announced this week with a boost for medical research funding.
The Association's members include prominent surgeons from around the world.
MIA leads the world-first study that finds anti–PD-1 antibody pembrolizumab increases the survival of patients
This is a landmark study, the first in a class of drugs that will change the future of treatment for all cancers.
Australia is the first country in the world to register anti-PD1 for the first line treatment of unresectable or metastatic melanoma in adults.
We have a winner!
Professor John Thompson, Executive Director at Melanoma Institute Australia, was one of 116 fellows appointed to the new Australian Academy of Health and Medical Sciences at a ceremony in Canberra on the 25th March.
Federal Minister for Health, the Hon. Sussan Ley, announced more than $14 million in funding for a research program to study the molecular determinants of risk, progression and treatment response in melanoma.
If you would like to download a bib for your Melanoma March, we have a selection for you to choose from, print and bring along with you on the day.
Manly Melanoma March has changed to a new location.
We did a short Q&A with two sisters who are raising funds for Melanoma March after sadly losing their mother in 2009. This is their second march and they have shared with us their fundraising tips.
We want to share with you what your valuable Melanoma March donation and fundraising goes towards and our Research Director, Graham Mann explains the national research project the funds will be going towards.
Evaluation of Groin Lymphadenectomy Extent for Metastatic Melanoma (EAGLE FM) clinical trial has recruited its first patient.
You are invited to provide comments for consideration by the Pharmaceutical Benefits Advisory Committee (PBAC). The PBAC will consider the registration of the anti-PD1 drug, Keytruda (pembrolizumab) at the next meeting in March.
Melanoma patient Joel Allsop was congratulated today on completing his participation in the international surgical clinical trial, known as MSLT-II. He was the first person in the world to complete the 10 years of follow-up for this trial.
Melanoma Institute Australia (MIA) has officially launched the 2015 ‘Melanoma March’ initiative in Melbourne.